🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million instances per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are deeply concerned about the rise in drug-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Global Access

According to findings detailed in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The study included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Clinicians treating patients have voiced optimism. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for public health efforts. This is deemed crucial to lessen the impact of the illness for people and to stop the proliferation of extremely resistant gonorrhoea around the world.